uniQure Announces $150 Million Proposed Public Offering
Rhea-AI Summary
uniQure (Nasdaq: QURE) commenced a proposed $150 million underwritten public offering of ordinary shares and, for certain investors, pre-funded warrants. All securities are offered by the company, with a planned 30-day option for underwriters to buy up to an additional $22.5 million in shares.
The deal is subject to market conditions and may not be completed. Leerink Partners and Stifel are bookrunning managers, and the offering uses uniQure’s effective shelf registration on Form S-3 filed in January 2025.
Positive
- Proposed $150 million underwritten equity and pre-funded warrant financing
- Additional $22.5 million underwriter option could increase gross proceeds
- Use of effective Form S-3 shelf can streamline capital access
Negative
- Equity and warrant issuance may result in shareholder dilution
- Offering size and completion remain uncertain and subject to market conditions
News Market Reaction – QURE
In the Jun 23 session, QURE gained 10.48%, reflecting a significant positive market reaction. Argus tracked a peak move of +7.2% during that session. Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 29 | Equity offering close | Negative | -1.7% | Closing of upsized equity raise with full underwriter option exercise. |
| Sep 25 | Offering pricing | Negative | +3.1% | Pricing of upsized equity deal with set share count and offer price. |
| Sep 24 | Proposed offering | Negative | +10.8% | Announcement of sizable proposed equity raise and underwriter option. |
| Jan 08 | Offering pricing | Negative | -9.8% | Pricing of share offering intended to raise specified gross proceeds. |
| Jan 07 | Proposed offering | Negative | -9.8% | Launch of underwritten offering of shares and pre-funded warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past equity offerings in QURE have typically triggered modestly negative moves, with a few notable upside exceptions.
Key Terms
underwritten public offering financial
pre-funded warrants financial
shelf registration statement regulatory
prospectus supplement regulatory
form s-3 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a
Leerink Partners and Stifel are acting as bookrunning managers for the proposed offering.
The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities Exchange Commission (the “SEC”) on January 7, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website at http://www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at +1 (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the completion, timing, and size of uniQure’s anticipated public offering, the grant to the underwriters of an option to purchase additional securities, and other statements identified by words such as "estimate," "plan," "project," "forecast," "intend," "will," "shall," "expect," "anticipate," "believe," "seek," "target," "continue," "could," "may," "might," "possible," "potential," "predict" and similar words or expressions.
Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms, or at all, continued interest in our rare disease portfolio, the ability to develop our product candidates and technologies, the impact of changes in the financial markets and global economic conditions, and other factors described under the heading "Risk Factors" in uniQure’s periodic securities filings with the SEC, including our Annual Report on Form 10-K filed with the SEC on March 2, 2026, our Quarterly Report on Form 10-Q filed on May 5, 2026, the preliminary prospectus supplement once filed with the SEC and the accompanying prospectus, and other filings that uniQure makes with the SEC from time to time. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and, except as required by law, uniQure assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
| uniQure Contacts For Investors: Chiara Russo Direct: 781-491-4371 Mobile: 617-306-9137 c.russo@uniQure.com | For Media: Tom Malone Direct: 339-970-7758 Mobile: 339-223-8541 t.malone@uniQure.com |
